ARTICLE | Discovery & Translation
BioCentury’s roundup of translational innovations
By Danielle Golovin, Senior Biopharma Analyst
March 23, 2024 12:27 AM UTC
AbbVie Inc. (NYSE:ABBV), part of the wave of companies diversifying antibody-drug conjugate (ADC) payloads and taking the modality beyond cancer, has published details about its Phase II ADC for rheumatoid arthritis in Science Translational Medicine.
The ADC, dubbed ABV-3773, contains an anti-TNF antibody that both neutralizes serum TNF and facilitates internalization of the ADC in inflamed tissues through TNF receptor-mediated endocytosis. The payload is a glucocorticoid receptor modulator that inhibits pro-inflammatory cytokine production when released in activated immune cells, avoiding the systemic side effects of standard glucocorticoid therapies. …
- SEO Powered Content & PR Distribution. Get Amplified Today.
- PlatoData.Network Vertical Generative Ai. Empower Yourself. Access Here.
- PlatoAiStream. Web3 Intelligence. Knowledge Amplified. Access Here.
- PlatoESG. Carbon, CleanTech, Energy, Environment, Solar, Waste Management. Access Here.
- PlatoHealth. Biotech and Clinical Trials Intelligence. Access Here.
- Source: https://www.biocentury.com/article/651831/abbvie-s-adc-for-inflammation-plus-heparegenix-s-liver-failure-therapy-and-more